Evaluation of the use of the Positive and Negative Syndrome Scale-Excited Component as a criterion for administration of p.r.n. medication

Journal of Psychiatric Practice

Volumn 14, Issue 2, 2008, Pages 105-113

  Chaichan, Warawat ^a  

^a Nakhonsawan Rajanakarindra Psychiatric Hospital   (Thailand)

Author keywords

Aggression; Agitation; Emergency psychiatry; p.r.n. medication; Positive and Negative Syndrome Scale (PANSS); Schizophrenia

Indexed keywords

CHLORPROMAZINE; DIAZEPAM; HALOPERIDOL; PSYCHOTROPIC AGENT;

ADULT; AGGRESSION; AGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MALE; MEDICAL INFORMATION; MEDICAL RECORD; MENTAL HOSPITAL; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; THAILAND;

ACUTE DISEASE; ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CRITICAL PATHWAYS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 41149094675     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000314317.79544.b4     Document Type: Article

References (36)

1. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000;61:5-10.
2. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med 2005;23:767-76.
3. Sadock BJ, Sadock VA. Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
4. Stephen RM. Schizophrenia: Somatic treatment. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's comprehensive textbook of psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2000:1199-210.
5. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
6. Owen C, Tarantello C, Jones M, et al. Violence and aggression in psychiatric units. Psychiatr Serv 1998;49:1452-7.
7. Whicher E, Morrison M, Douglas-Hall P. "As required" medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev 2002;(2):CD003441.
8. McLaren S, Browne FW, Taylor PJ. A study of psychotropic medication given "as required" in a regional secure unit. Br J Psychiatry 1990;156:732-5.
9. Craig TJ, Bracken J. An epidemiologic study of p.r.n./stat medication use in a state psychiatric hospital. Ann Clin Psychiatry 1995;7:57-64.
10. Usher K, Lindsay D, Sellen J. Mental health nurses' p.r.n. psychotropic medication administration practices. J Psychiatr Ment Health Nurs 2001;8:383-90.
11. Gray RJ, Smedley NS, Thomas BL. Administration of p.r.n. medication by mental health nurses. Br J Nurs 1996;5:1317-22.
12. Geffen J, Cameron A, Sorensen L, et al. Pro re nata medication for psychoses: The knowledge and beliefs of doctors and nurses. Aust N Z J Psychiatry 2002;36:642-8.
13. Szczesny S, Miller M. P.r.n. medication use in inpatient psychiatry. J Psychosoc Nurs Ment Health Serv 2003;41:16-21.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
15. Kay SR, Opler LA, Fiszbein A, et al. Positive and Negative Syndrome Scale (PANSS) technical manual. Toronto, Ontario, Canada: Multi-Health Systems; 2006.
16. Emsley R, Rabinowitz J, Torreman M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res 2003;61:47-57.
17. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.
18. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res 1994;53:31-40.
19. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull 1990;16:537-45.
20. Eli Lilly and Company. Briefing Document for Zyprexa intramuscular (olanzapine for injection). Submitted to FDA Psychopharmacological Drugs Advisory Committee. February 14, 2001 (available at:www.fda.gov/ohrms/dockets/ ac/01/briefing/3685b1_01_lilly.pdf, accessed February 9, 2007).
21. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 2004;68:331-7.
22. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153-7.
23. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-34.
24. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504.
25. Currier GW, Trenton AJ, Walsh PG, et al. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract 2006;12:223-8.
26. San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006;21:539-43.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.
28. Nilchaikovit T, Uneanong S, Kessawai D, et al. The Thai version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia: Criterion validity and interrater reliability. J Med Assoc Thai 2000;83:646-51.
29. White L, Opler LA, Harvey PD, et al. Activation symptoms and discharge in elderly chronic schizophrenic inpatients. J Nerv Ment Dis 2004;192:880-3.
30. Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986;143:35-9.
31. Lehman AF, Steinwachs DM. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10.
32. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7.
33. Opler LA, Opler MG, Malaspina D. Reducing guesswork in schizophrenia treatment: PANSS can target and gauge therapy, predict outcomes in clinical practice. Current Psychiatry 2006;5:76-84.
34. Mackay I, Paterson B, Cassells C. Constant or special observations of inpatients presenting a risk of aggression or violence: Nurses' perceptions of the rules of engagement. J Psychiatr Ment Health Nurs 2005;12:464-71.
35. Curtis J, Capp K. Administration of "as needed" psychotropic medication: A retrospective study. Int J Ment Health Nurs 2003;12:229-34.
36. Thapa PB, Palmer SL, Owen RR, et al. P.R.N. (as needed) orders and exposure of psychiatric inpatients to unnecessary psychotropic medications. Psychiatr Serv 2003;54:1282-6.